STOCK TITAN

Purple Biotech Ltd - PPBT STOCK NEWS

Welcome to our dedicated news page for Purple Biotech (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Purple Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Purple Biotech's position in the market.

Rhea-AI Summary
Purple Biotech closes registered direct offering, raising approximately $5 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags
-
Rhea-AI Summary
Purple Biotech announces purchase and sale agreement for 4,347,827 ADSs at $1.15 per ADS in a registered direct offering. Concurrent private placement includes unregistered warrants to purchase up to 4,347,827 ADSs at $1.25 per ADS. Gross proceeds expected to be approximately $5 million. Proceeds will be used for development of oncology therapeutic candidates and general working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
-
Rhea-AI Summary
Purple Biotech reports new biomarker data for CM24 oncology drug at AACR conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
Rhea-AI Summary
Purple Biotech provides clinical updates on NT219, a dual inhibitor of IRS 1/2 and STAT3, for second-line treatment of R/M SCCHN. Highest dose cohort shows anti-tumor activity with 2 out of 4 patients demonstrating confirmed partial response. Target engagement confirmed in patients' biopsies. Phase 2 study being designed. Positive outlook for NT219 in combination with cetuximab in 2L R/M SCCHN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.18%
Tags
-
Rhea-AI Summary
Purple Biotech to present Phase 1 study results at AACR conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
conferences
-
Rhea-AI Summary
Purple Biotech announces financial results for Q2 2023, with clinical trials progressing faster than expected
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
Rhea-AI Summary
Purple Biotech announces positive results from Phase 1 study of CM24, a first-in-class anti-CEACAM1 monoclonal antibody, in refractory PDAC patients. The immunotherapy combination of CM24 and nivolumab demonstrated comparable Overall Survival rates to chemotherapy in third-line patients. Phase 2 study is enrolling as expected, with initial data expected by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Purple Biotech Ltd

Nasdaq:PPBT

PPBT Rankings

PPBT Stock Data

15.97M
235.63M
4.05%
9.36%
0.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
132 Menachem Begin Road

About PPBT

kitov pharmaceuticals ltd. is a financial services company located in israel.